menu
    • menu
    [{"orgOrder":0,"company":"Mustang Bio","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MB-101","moa":"IL-13 alpha-2","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ City of Hope"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"MB-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for MB-101

    Menu

    MB-101

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mustang Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Mustang Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MB-101,MB-108

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2...

                            Details : MB-109 is Mustang’s designation for the treatment regimen combining MB-101 (COH-developed IL13Rα2‐targeted CAR-T cell therapy) with MB-108 (Nationwide-developed HSV-1 oncolytic virus), which is investigated for Recurrent Glioblastoma and High-Grade ...

                            Brand Name : MB-109

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 26, 2023

                            Lead Product(s) : MB-101,MB-108

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mustang Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Mustang Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MB-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : City of Hope

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital A...

                            Details : MB-101, an IL13Rα2-targeted CAR T cell therapy demonstrate durable complete responses in GBM based on a 54-patient Phase 1 trial, as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency ...

                            Brand Name : MB-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 09, 2022

                            Lead Product(s) : MB-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : City of Hope

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth